MedTrace Logo

Safety and Efficacy of HB-1 for Panic Disorder

NCT05071430 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of potential new treatment called "HB-1" versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with panic disorder.

Conditions

  • Panic Disorder

Interventions

DRUG

HB-01

HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.

DRUG

Placebo

HB-1 matched placebo

Sponsors & Collaborators

  • Cognitive Research Corporation

    collaborator INDUSTRY

  • Honeybrains Biotech LLC

    lead INDUSTRY

Principal Investigators

  • David Walling · Collaborative NeuroScience Research, Garden Grove, CA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-03
Primary Completion
2022-12-12
Completion
2022-12-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05071430 on ClinicalTrials.gov